[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349821-105":59,"doc-detail-349821-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-characteristics-and-spatial-transcriptome-analysis-of-nonsmall-cell-lung-cancers-exhibiting-early-alectinib-resistance-a-retrospective-olcsg-study","Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance - A Retrospective OLCSG Study","","Some anaplastic lymphoma kinase (ALK) rearrangement–positive lung cancers develop early resistance to alectinib within 3 months. This retrospective OLCSG study evaluated clinical and molecular features in unresectable stage III/IV patients and selected recurrent cases treated with alectinib between 2013 and 2021 across nine hospitals. Among 103 patients, early resistance showed significantly shorter overall survival and higher rates of brain metastases, alongside elevated inflammatory markers including neutrophil-to-lymphocyte ratio (NLR). Spatial transcriptomics and immunohistochemistry linked early resistance to annexin A1 (ANXA1) upregulation, with interleukin 6 stimulation reducing alectinib sensitivity and ANXA1 knockdown restoring it.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-characteristics-and-spatial-transcriptome-analysis-of-nonsmall-cell-lung-cancers-exhibiting-early-alectinib-resistance-a-retrospective-olcsg-study/349821/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-characteristics-and-spatial-transcriptome-analysis-of-nonsmall-cell-lung-cancers-exhibiting-early-alectinib-resistance-a-retrospective-olcsg-study/349821.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What defines early alectinib resistance in this study?","Question",{"text":112,"@type":113},"Early resistance was defined as progression within 3 months, based on how prior major trials characterize low progression rates during that interval.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which clinical factors were associated with early resistance?",{"text":117,"@type":113},"Brain metastases and high neutrophil-to-lymphocyte ratio (NLR) were identified as significant predictors of early resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"How does ANXA1 relate to alectinib resistance?",{"text":121,"@type":113},"Spatial transcriptome analysis and immunohistochemistry showed ANXA1 upregulation in the early resistance group; interleukin-6 stimulation increased ANXA1 expression, reduced alectinib sensitivity, and ANXA1 knockdown improved sensitivity in resistant cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349821,1790169190,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0545](https://doi.org/10.1158/2767-9764.CRC-25-0545)  OPEN ACCESS  \nClinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study  \nTadahiro Kuribayashi1, Go Makimoto2, Kadoaki Ohashi2, Shuta Tomida3, Hirofumi Inoue3, Toshihide Yokoyama4, Shoichi Kuyama5, Yuka Kato6, Kenichiro Kudo7, Naokatsu Horita8, Hiroe Kayatani9, Masaaki Inoue10, Keisuke Sugimoto11, Kiichiro Ninomiya3, Yoshinobu Maeda1, Yosuke Togashi2,12, and Katsuyuki Hotta13  \n􀀶  \nABSTRACT  \nSome anaplastic lymphoma kinase (ALK) gene rearrangement–positive lung cancers show early resistance, within 3 months, to alectinib. This study investigated the clinical and molecular characteristics of these patients. We analyzed patients with unresectable stage III/IV disease without indications for radical radiotherapy and recurrent ALK-positive lung cancer who received alectinib as the primary ALK tyrosine kinase inhibitor between 2013 and 2021 at nine hospitals. In total, 103 patients were included. The median age was 65 years; 44 were male and 22 had brain metastases. The median progression-free survival and overall survival (OS) were 28.7 and 80.6 months. Nineteen patients treated for ≤3 months and 84 treated for >3 months were categorized into the early resistance and responder groups, respectively. The early resistance group had significantly shorter OS (8.4 months vs. not estimable, P \u003C 0.001) and was significantly more likely to have brain metastases (42% vs. 17%, P ¼ 0.027). They also showed elevated inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR). Univariate analysis identified brain metastases and high NLR as significant predictors of early  \nresistance. Spatial transcriptome analysis and immunohistochemical staining revealed upregulation of annexin A1 (ANXA1), a calciumdependent phospholipid-binding protein involved in inflammation and cancer progression, in the early resistance group. Interleukin 6 stimulation, prompted by elevated inflammatory markers, increased ANXA1 expression and reduced alectinib sensitivity. Knockdown of ANXA1 improved alectinib sensitivity in alectinib-resistant cells. In conclusion, brain metastases and high NLR are associated with early resistance. ANXA1 may play an important role in mediating early resistance. New treatment options for the early resistance group are required.  \nSignificance: Some ALK-positive lung cancers show early resistance to alectinib. This study found brain metastases and elevated NLR associated with early resistance. Spatial transcriptomics and functional analysis suggested involvement of ANXA1 . These results reveal clinical and molecular biomarkers that may guide treatment strategies for early resistance to alectinib.  \nIntroduction  \nLung cancer has the highest mortality rate worldwide ( 1) . Anaplastic lymphoma kinase (ALK) gene rearrangement–positive non–small cell lung  \n1Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. 2Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan. 3Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan. 4Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, Kurashiki, Japan. 5Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan. 6Department of Thoracic Oncology and Medicine, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan. 7Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan. 8Department of Respiratory Medicine, Kure Kyosai Hospital, Kure, Japan. 9Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan. 10Department of Chest Surgery, Shimonoseki City Hospital, Shimon","cbCaisELHqtHoR6n","https://ap.wps.com/l/cbCaisELHqtHoR6n","pdf",11710238,"English","# Abstract\n# Significance\n# Introduction\n## Lung cancer burden and ALK-positive NSCLC background\n## Definition and clinical importance of early resistance\n# Methods and study cohort (retrospective OLCSG)\n# Results\n## Clinical outcomes and prognostic factors\n## Inflammatory markers and predictors\n## Spatial transcriptome and ANXA1 findings\n# Discussion\n## Mechanistic model and therapeutic implications","[{\"question\":\"What defines early alectinib resistance in this study?\",\"answer\":\"Early resistance was defined as progression within 3 months, based on how prior major trials characterize low progression rates during that interval.\"},{\"question\":\"Which clinical factors were associated with early resistance?\",\"answer\":\"Brain metastases and high neutrophil-to-lymphocyte ratio (NLR) were identified as significant predictors of early resistance.\"},{\"question\":\"How does ANXA1 relate to alectinib resistance?\",\"answer\":\"Spatial transcriptome analysis and immunohistochemistry showed ANXA1 upregulation in the early resistance group; interleukin-6 stimulation increased ANXA1 expression, reduced alectinib sensitivity, and ANXA1 knockdown improved sensitivity in resistant cells.\"}]","Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance - A Retrospective OLCSG Study | PDF",1790085772,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e41a21f6370eb7ae1e81d9f42bc0b81.webp",983,1263,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ff15e651eb1cc72c9410a60f7eaf1fb.webp",982,1262,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22ed867ce9aec26186edd616d2557d97.webp",981,1261,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87a93e251801a01137b9fd862ad0b1c2.webp",980,1259]